Citations

Mayo Clinic

Showing 10 of 108522 citations.

Interaction between endoplasmic/sarcoplasmic reticulum stress (ER/SR stress), mitochondrial signaling and Ca2+ regulation in airway smooth muscle (ASM)
Delmotte, Philippe , Sieck, Gary C. , Sieck, Gary

Canadian Journal of Physiology and Pharmacology | November 25, 2014 | Volume: 93 | Issue: 2 | Pages: 97-110

10.1139/cjpp-2014-0361 | PMID 25506723 Get It

Airway inflammation is a key aspect of diseases such as asthma. Several inflammatory cytokines (e.g., TNFα and IL-13) increase cytosolic Ca2+ ([Ca2+]cyt) responses to agonist stimulation and Ca2+ sensitivity of force generation, thereby enhancing airway smooth muscle (ASM) contractility (hyper-reactive state). Inflammation also induces ASM proliferation and remodeling (synthetic state). In normal ASM, the transient elevation of [Ca2+]cyt induced by agonists leads to a transient increase in mitochondrial Ca2+ ([Ca2+]mito) that may be important in matching ATP production with ATP consumption. In human ASM (hASM) exposed to TNFα and IL-13, the transient increase in [Ca2+]mito is blunted despite enhanced [Ca2+]cyt responses. We also found that TNFα and IL-13 induce reactive oxidant species (ROS) formation and endoplasmic/sarcoplasmic reticulum (ER/SR) stress (unfolded protein response) in hASM. ER/SR stress in hASM is associated with disruption of mitochondrial coupling with the ER/SR membrane, which relates to reduced mitofusin 2 (Mfn2) expression. Thus, in hASM it appears that TNFα and IL-13 result in ROS formation leading to ER/SR stress, reduced Mfn2 expression, disruption of mitochondrion–ER/SR coupling, decreased mitochondrial Ca2+ buffering, mitochondrial fragmentation, and increased cell proliferation.
Single-Incision Laparoscopic Ileal Pouch-Anal Anastomosis in Children—How Does It Compare to a Laparoscopic-Assisted Approach?
Polites, Stephanie F. , Zarroug, Abdalla E., Moir, Christopher R. , Potter, D. Dean

Journal of Laparoendoscopic & Advanced Surgical Techniques | November 25, 2014 | Volume: 25 | Issue: 2 | Pages: 167-171

10.1089/lap.2014.0297 | PMID 25423290 Get It

Challenges in the Management of Giant Intraductal Breast Papilloma
Fatemi, Yasaman , Hurley, Rachel M. , Grant, Clive S., Henrichsen, Tara L. , Chen, Beiyun, Ghosh, Karthik, Grant, Clive, Henrichsen, Tara

Clinical Case Reports | November 25, 2014 | Volume: 3 | Issue: 1 | Pages: 7-10

10.1002/ccr3.116 | PMID 25678964 Get It

Key Clinical MessageThe differential diagnosis of a large breast mass in a post‐menopausal woman can include both benign and malignant etiologies. Although rare, diagnosis of giant intraductal papilloma must be considered in the differential. Furthermore, although benign, papillomas presenting as a large breast mass affecting the skin require extensive breast surgical treatment.
Before it crumbles: Fulminant Hepatic Failure secondary to Hodgkin's Lymphoma
Karmacharya, Paras , Bhandari, Naresh, Aryal, Madan Raj , Pandit, Aashrayata A., Pathak, Ranjan , Ghimire, Sailu, Shrestha, Pragya , Pandit, Aashrayata Aryal, Bhatt, Vijaya Raj , Karmacharya, Paras

Journal of Community Hospital Internal Medicine Perspectives | November 25, 2014 | Volume: 4 | Issue: 5 | Pages: 25821

10.3402/jchimp.v4.25821 | PMID 25432655 Get It

Patients’ experiences from symptom onset to initial treatment for atrial fibrillation
McCabe, Pamela J. , Rhudy, Lori M. , DeVon, Holli A.

Journal of Clinical Nursing | November 25, 2014 | Volume: 24 | Issue: 5-6 | Pages: 786-796

10.1111/jocn.12708 | PMID 25421608 Get It

Aims and objectives To describe patients’ experiences from symptom onset to initial treatment for atrial fibrillation. Background The estimated number of individuals with atrial fibrillation globally in 2010 was 33·5 million. World‐wide, each year, new cases of atrial fibrillation approach 5 million, and prevalence will increase 2·5‐fold by 2050. As a result, clinicians worldwide will treat a growing number of patients with atrial fibrillation. Early intervention to promote atrial fibrillation self‐management is critical to reduce associated complications of stroke and heart failure. Greater understanding of patients’ experiences from symptom onset to initial treatment for atrial fibrillation is needed to guide development of interventions to promote early effective self‐management. Design A descriptive qualitative design was used. Methods Twenty females and 21 males at an academic medical centre were interviewed using open‐ended questions to explore their experiences from symptom onset to initial treatment for atrial fibrillation. Data were analysed using qualitative content analysis. Results Participants’ mean age was 64·3 (SD = 10·1) years. Four themes were identified: (1) misinterpreting symptoms; (2) discovering the meaning of atrial fibrillation; (3) facing fears, uncertainty, and moving to acceptance; and (4) receiving validation and reassurance. Participants lacked knowledge of atrial fibrillation and took cues from providers’ responses to appraise symptoms and diagnosis. Fear and uncertainty were reduced when providers initiated prompt treatment and took time to explain atrial fibrillation. Patients appreciated receiving clear information about atrial fibrillation, were engaged in learning, and motivated to participate in their care. Conclusions Providers played a critical role in helping patients to develop an accurate understanding of atrial fibrillation, to cope with the new diagnosis, and motivated them to engage in effective self‐management. Relevance to clinical practice Insight into participant experiences from symptom onset to initial treatment for atrial fibrillation may inform development of interventions to promote effective atrial fibrillation self‐management.
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
Budd, G. Thomas , Hobday, Timothy J. , Stewart, James A. , Salim, Muhammad , Cho, Jonathan K., Rinn, Kristine , Albain, Kathy S. , Chew, Helen K. , Burton, Gary V., Moore, Timothy D., Srkalović, Gordan , Flaherty, Lawrence E. , Livingston, Robert B., Lew, Danika L., Budd, George T, Rinn, Kristine J, McGregor, Bradley A. , Barlow, William E. , Moore, Halle C. F. , Isaacs, Claudine , Gralow, Julie R. , Hortobágyi, Gabriel N.

Journal of Clinical Oncology | November 25, 2014 | Volume: 33 | Issue: 1 | Pages: 58-64

10.1200/jco.2014.56.3296 | PMID 25422488 Get It

Purpose To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients and Methods A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. With 3,250 patients, a disease-free survival (DFS) hazard ratio of 0.82 for each randomization could be detected with 90% power with two-sided α = .05. Overall survival (OS) was a secondary outcome. Results Interim analyses crossed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-every-2-weeks regimens. After a median follow-up of 6 years, a significant interaction developed between the two randomization factors (DFS P = .024; OS P = .010) in the 2,716 patients randomly assigned in the original design, which precluded interpretation of the two factors separately. Comparing all four arms showed a significant difference in OS (P = .040) but not in DFS (P = .11), with all treatments given once every 2 weeks associated with the highest OS. This difference in OS seemed confined to patients with hormone receptor–negative/human epidermal growth factor receptor 2 (HER2) –negative tumors (P = .067), with no differences seen with hormone receptor–positive/HER2-negative (P = .90) or HER2-positive tumors (P = .40). Conclusion Patients achieved a similar DFS with any of these regimens. Subset analysis suggests the hypothesis that once-every-2-weeks dosing may be best for patients with hormone receptor–negative/HER2-negative tumors.
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma
Mir, Muhammad A. , Maurer, Matthew J. , Ziesmer, Steven C., Macon, William R. , Link, Brian K. , Syrbu, Sergei , Friedberg, Jonathan W. , Press, Oliver W. , Novak, Anne J. , Ansell, Stephen M. , Slager, Susan L. , Habermann, Thomas M. , Witzig, Thomas E. , LeBlanc, Michael , Cerhan, James R. , Maurer, Matthew , Press, Oliver , Link, Brian K , Syrbu, Sergei

Blood | November 24, 2014 | Volume: 125 | Issue: 6 | Pages: 992-998

10.1182/blood-2014-06-583369 | PMID 25422100 Get It

Key Points Elevated IL-2R, IL-1RA, and CXCL9 are associated with shorter event-free survival in newly diagnosed FL, treated with chemoimmunotherapy. Increased serum IL-12 and IL-1RA is associated with shorter event-free survival in patients who were observed or treated with rituximab alone.
Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma
Koh, Mei Yee , Nguyen, Vuvi, Lemos, Robert, Darnay, Bryant G., Kiriakova, Galina M., Abdelmelek, Mena, Ho, Thai H. , Monzon, Federico A. , Powis, Garth , Karam, Jose Antonio , Jonasch, Eric W. , Ho, Thai , Koh, Mei Yee

Cancer Research | November 24, 2014 | Volume: 75 | Issue: 2 | Pages: 316-329

10.1158/0008-5472.can-13-2190 | PMID 25421578 Get It

Abstract Clear-cell renal cell cancer (CRCC) is initiated typically by loss of the tumor-suppressor VHL, driving constitutive activation of hypoxia-inducible factor-1 (HIF1) and HIF2. However, whereas HIF1 has a tumor-suppressor role, HIF2 plays a distinct role in driving CRCC. In this study, we show that the HIF1α E3 ligase hypoxia-associated factor (HAF) complexes with HIF2α at DNA to promote HIF2-dependent transcription through a mechanism relying upon HAF SUMOylation. HAF SUMOylation was induced by hypoxia, whereas HAF-mediated HIF1α degradation was SUMOylation independent. HAF overexpression in mice increased CRCC growth and metastasis. Clinically, HAF overexpression was associated with poor prognosis. Taken together, our results show that HAF is a specific mediator of HIF2 activation that is critical for CRCC development and morbidity. Cancer Res; 75(2); 316–29. ©2014 AACR.
Next Generation Sequencing in Clinical Diagnostics: Experiences of Early Adopters
Lyon, Elaine, Cockerill, Franklin R., Bale, Sherri J., Beadling, Carol , Bry, Lynn , Hagenkord, Jill , Kulkarni, Shashikant, Press, Richard D. , Richards, C. Sue , Press, Richard

Clinical Chemistry | November 24, 2014 | Volume: 61 | Issue: 1 | Pages: 41-49

10.1373/clinchem.2014.222687 | PMID 25421800 Get It

Research Priorities for the Influence of Gender on Diagnostic Imaging Choices in the Emergency Department Setting
Ashurst, John , Cherney, Alan R., Evans, Elizabeth , Hall, M. Kennedy , Kline, Jeffrey A. , Mitchell, Alice M. , Mills, Angela M. , Weigner, Michael B., Hess, Erik P. , Moore, Christopher L. , Mills, Angela M

Academic Emergency Medicine | November 24, 2014 | Volume: 21 | Issue: 12 | Pages: 1431-1437

10.1111/acem.12537 | PMID 25420885 Get It